All Outputs (117)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial (2021)
Journal Article
Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., …Allen, L. (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, 398(10303), 856-869. https://doi.org/10.1016/S0140-6736%2821%2901694-9

Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZ... Read More about Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study (2021)
Journal Article
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., … ISARIC4C investigators, O. B. O. T. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), 223-237. https://doi.org/10.1016/S0140-6736%2821%2900799-6

Background COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care sys... Read More about Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study (2021)
Journal Article
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., …Young, P. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), 223-237. https://doi.org/10.1016/S0140-6736%2821%2900799-6

BackgroundCOVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care syste... Read More about Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study (2021)
Journal Article
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., …Young, P. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. The Lancet Microbe, 2(8), e354-e365. https://doi.org/10.1016/s2666-5247%2821%2900090-2

Background Microbiological characterisation of co-infections and secondary infections in patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary infections, and a... Read More about Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK (2021)
Journal Article
Docherty, A. B., Mulholland, R. H., Lone, N. I., Cheyne, C. P., De Angelis, D., Diaz-Ordaz, K., …Young, P. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine, 9(7), 773-785. https://doi.org/10.1016/S2213-2600%2821%2900175-2

Background: Mortality rates in hospitalised patients with COVID-19 in the UK appeared to decline during the first wave of the pandemic. We aimed to quantify potential drivers of this change and identify groups of patients who remain at high risk of d... Read More about Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data (2021)
Journal Article
Shaw, R. H., Stuart, A., Greenland, M., Liu, X., Van-Tam, J. S. N., Snape, M. D., & COM-COV Study Group. (2021). Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet, 397(10289), 2043-2046. https://doi.org/10.1016/S0140-6736%2821%2901115-6

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK (2021)
Journal Article
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., …Young, P. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine, 9(7), 699-711. https://doi.org/10.1016/s2213-2600%2821%2900013-8

Background Studies of patients admitted to hospital with COVID-19 have found varying mortality outcomes associated with underlying respiratory conditions and inhaled corticosteroid use. Using data from a national, multicentre, prospective cohort, we... Read More about Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.

Decline in seasonal influenza vaccine effectiveness with vaccination program maturation: A systematic review and meta-analysis (2021)
Journal Article
Okoli, G. N., Racovitan, F., Abdulwahid, T., Hyder, S. K., Lansbury, L., Righolt, C. H., …Nguyen-Van-Tam, J. S. (2021). Decline in seasonal influenza vaccine effectiveness with vaccination program maturation: A systematic review and meta-analysis. Open Forum Infectious Diseases, 8(3), Article ofab069. https://doi.org/10.1093/ofid/ofab069

Objectives Evidence suggests repeated influenza vaccination may reduce vaccine effectiveness (VE). Using influenza vaccination program maturation (number of years since program inception) [PM] as proxy for population-level repeated vaccination, we... Read More about Decline in seasonal influenza vaccine effectiveness with vaccination program maturation: A systematic review and meta-analysis.

Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus (2021)
Journal Article
Al-Beltagi, S., Preda, C. A., Goulding, L. V., James, J., Pu, J., Skinner, P., …Chang, K. (2021). Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus. Viruses, 13(2), Article 234. https://doi.org/10.3390/v13020234

The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to in-clude antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass va... Read More about Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.

Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia (2021)
Journal Article
Moreno, G., Rodríguez, A., Sole-Violán, J., Martín-Loeches, I., Díaz, E., Bodí, M., …Torres, A. (2021). Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Research, 7(1), Article 00888-2020. https://doi.org/10.1183/23120541.00888-2020

Background The relationship between early oseltamivir treatment (within 48 h of symptom onset) and mortality in patients admitted to intensive care units (ICUs) with severe influenza is disputed. This study aimed to investigate the association betwee... Read More about Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia.

Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study (2021)
Journal Article
Gupta, R. K., Harrison, E. M., Ho, A., Docherty, A. B., Knight, S. R., van Smeden, M., …Young, P. (2021). Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, 9(4), 349-359. https://doi.org/10.1016/s2213-2600%2820%2930559-2

Background Prognostic models to predict the risk of clinical deterioration in acute COVID-19 cases are urgently required to inform clinical management decisions. Methods We developed and validated a multivariable logistic regression model for in... Read More about Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score (2020)
Journal Article
Knight, S. R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T. M., …Harrison, E. M. (2020). Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, 370, Article m3339. https://doi.org/10.1136/bmj.m3339

Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational cohort study. Setting International Severe Acute Respiratory and... Read More about Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.

Clinical characteristics of children and young people admitted to hospital with Covid-19 in United Kingdom: prospective multicentre observational cohort study (2020)
Journal Article
Swann, O. V., Holden, K. A., Turtle, L., Pollock, L., Fairfield, C. J., Drake, T. M., …Semple, M. G. (2020). Clinical characteristics of children and young people admitted to hospital with Covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ, 370, Article m3249. https://doi.org/10.1136/bmj.m3249

Objective To characterise the clinical features of children and young people admitted to hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK and explore factors associated with admission... Read More about Clinical characteristics of children and young people admitted to hospital with Covid-19 in United Kingdom: prospective multicentre observational cohort study.

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score (2020)
Other
Knight, S. R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T. M., …Harrison, E. M. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Objectives To develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19. Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Conso... Read More about Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.

Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases (2020)
Journal Article
Bueno de Mesquita, P. J., Nguyen‐Van‐Tam, J., Killingley, B., Enstone, J., Lambkin‐Williams, R., Gilbert, A. S., …Milton, D. K. (2021). Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases. Influenza and Other Respiratory Viruses, 15(1), 154-163. https://doi.org/10.1111/irv.12790

Background It has long been known that nasal inoculation with influenza A virus produces asymptomatic to febrile infections. Uncertainty persists about whether these infections are sufficiently similar to natural infections for studying human‐to‐hum... Read More about Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases.

Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study (2020)
Working Paper
Swann, O. V., Holden, K. A., Turtle, L., Pollock, L., Fairfield, C. J., Drake, T. M., …ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators. Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study

Objective To characterise the clinical features of children and young people admitted to hospital with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK, and explore factors associated with admissio... Read More about Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study.

Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment (2020)
Journal Article
Nguyen-Van-Tam, J. S., Killingley, B., Enstone, J., Hewitt, M., Pantelic, J., Grantham, M. L., …for the EMIT Consortium. (2020). Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment. PLoS Pathogens, 16(7), Article e1008704. https://doi.org/10.1371/journal.ppat.1008704

Uncertainty about the importance of influenza transmission by airborne droplet nuclei generates controversy for infection control. Human challenge-transmission studies have been supported as the most promising approach to fill this knowledge gap. Hea... Read More about Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.

Cumulative incidence of post?infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis (2020)
Journal Article
Nguyen‐Van‐Tam, J., Wyffels, V., Smulders, M., Mazumder, D., Tyagi, R., Gupta, N., …Fleischhackl, R. (2020). Cumulative incidence of post‐infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis. Influenza and Other Respiratory Viruses, 14(6), 730-738. https://doi.org/10.1111/irv.12770

Background: Respiratory syncytial virus (RSV) infection is implicated in subsequent development of asthma/wheezing (AW) among term and pre-term infants. We describe the cumulative incidence of AW among hospitalized and ambulatory neonates/infants/tod... Read More about Cumulative incidence of post?infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis.

Features of 20?133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study (2020)
Journal Article
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., …Semple, M. G. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, 369, Article m1985. https://doi.org/10.1136/bmj.m1985

Objective: To characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe... Read More about Features of 20?133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (2020)
Other
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., …Semple, M. G. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Objective: To characterize the clinical features of patients with severe COVID-19 in the UK. Design: Prospective observational cohort study with rapid data gathering and near real-time analysis, using a pre-approved questionnaire adopted by the WHO.... Read More about Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol.